* K-V says divestment to help focus on women's health
* Shares up 16 pct
June 17 K-V Pharmaceutical Co KVa.N said it
agreed to sell its generic business unit to Zydus
Pharmaceuticals, a subsidiary of India-based drugmaker Cadila
Healthcare , for $60 million in cash.
K-V Pharma said its decision to divest Nesher
Pharmaceuticals Inc to Zydus is in line with its strategy to
focus on women's health segment.
Jefferies & Co acted as financial adviser to K-V Pharma for
the deal, which is expected to close in the second quarter of
KV's 2012 fiscal year.
Class A shares of K-V were up 11 percent at $2.66 in morning
trade on the New York Stock Exchange. They had touched a high of
$2.75 earlier in the session.
(Reporting by Anand Basu in Bangalore; Editing by Sriraj